Logo
x

Search category

Subscribe Now

All Posts by Date

Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

  • May 24, 2022
United Therapeutics’ Tyvaso DPI Receives the US FDA’s Approval for Treatment of PAH and PH-ILD

United Therapeutics’ Tyvaso DPI Receives the US FDA’s Approval for Treatment of PAH and PH-ILD

  • May 24, 2022
Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

  • May 24, 2022
UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axS...

  • May 24, 2022
Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcera...

  • May 24, 2022
ImmuntyBio Submits Biologics License Application for N-803 + BCG to Treat BCG-unresponsive NMIBC CIS

ImmuntyBio Submits Biologics License Application for N-803 + BCG to Treat BCG-unresponsive NMIBC CIS

  • May 24, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.